Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
|Articles|February 16, 2022
Pre-Exposure Prophylaxis and Antiretroviral Therapy Set UK on Track to Eliminate HIV
Author(s)Nina Cosdon
Due to policies rolling out HIV pre-exposure prophylaxis (PrEP) and commencing antiretroviral therapy at diagnosis, the UK is on track to eliminate new HIV infections among gay and bisexual men in approximately 25 years.
Advertisement
Having
One study, presented virtually at the 2022
For multiple sources of data on HIV among gay and bisexual men in the UK, Cambiano and fellow investigators calibrated an individual-based, stochastic HIV synthesis model. They compared new HIV infections in 2020 with what the counterfactual incidence may have been: if condom use from 2013 was low, if HIV testing remained stable from 2013, if the policy of beginning antiretroviral therapy (ART) upon HIV diagnosis had not been implemented in 2015, and if a
The investigators calculated hypothetical HIV rates as if each of these factors driving down infections had never been implemented. Additionally, they projected future HIV incidence if the current policies continued.
The results showed that the greatest reducer of HIV infections in 2020 was PrEP, followed by beginning an ART regimen at diagnosis. The investigators estimated that if PrEP had not been introduced, HIV rates among gay and bisexual men would have been 52% higher. Without commencing ART at the time of diagnosis, HIV infections would have been 22% higher.
In 2020, the HIV incidence rate among gay and bisexual men 15-64 years old was 1.7 per 1000 person-years. It is projected to decline to .55 per 1000 person-years in 2030 and to .23 per 1000 person-years by 2040. The investigators found that the UK is on track to eliminate HIV incidence (as defined by <1/1000 person-years) among gay and bisexual men in the next 17-33 years.
The research, “Contributions to the Decline in HIV Incidence among GBM in the UK: A Modelling Study,” was presented virtually during the
Advertisement
Related to this article
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.
The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
Advertisement
Advertisement